Combined heart and liver transplantation for homozygous familial hypercholesterolaemia: 35-year post-operative outcomes.

Rona Jalandari, Fatima Omar, Fawzi Lazem, Mahmoud Barbir
{"title":"Combined heart and liver transplantation for homozygous familial hypercholesterolaemia: 35-year post-operative outcomes.","authors":"Rona Jalandari, Fatima Omar, Fawzi Lazem, Mahmoud Barbir","doi":"10.21542/gcsp.2026.38","DOIUrl":null,"url":null,"abstract":"<p><p>Combined heart-liver transplantation (CHLT) is an exceptionally rare multi-organ procedure undertaken in patients with concurrent end-stage cardiac and hepatic disease, or in those with inherited metabolic disorders-most notably homozygous familial hypercholesterolaemia (HoFH)-in which defective hepatic LDL receptor (LDL-R) function drives progressive and otherwise irreversible cardiovascular injury. We report a 35-year follow-up of a female patient who underwent simultaneous orthotopic cardiac and liver transplantation on 13 September 1990 for HoFH complicated by severe ischaemic cardiomyopathy and aortic valve stenosis. Pre-operative serum low-density lipoprotein cholesterol (LDL-C) was 13 mmol/L, refractory to all pharmacological interventions available at the time. Transplantation produced immediate normalisation of LDL-C to 2.1 mmol/L, reflecting instantaneous restoration of donor hepatic LDL-R function-consistent with the landmark observations reported by Bilheimer, Goldstein, Brown, and Starzl<sup>1, 2</sup>. This normalisation has been broadly maintained across three and a half decades of follow-up. Lipid-lowering therapy was commenced post-operatively to augment the normalised lipid profile, and dramatic regression of tendon xanthomata was documented within six months of transplantation<sup>11</sup>. Cardiac graft function has remained preserved, with ejection fraction (EF) of 64-68% on recent echocardiography and no inducible ischaemia on sequential myocardial perfusion scintigraphy (MPS) in May 2025. Progressive cardiac allograft vasculopathy (CAV) has been identified on coronary CT angiography (CTCA) in 2024 but without haemodynamic consequence. Rejection burden across 35 years has been remarkably low-comprising a mild episode at three weeks post-transplant and a single biopsy-confirmed Grade 1R episode in 2013-consistent with the hepatic immunological privilege hypothesis first elaborated by Calne and subsequently substantiated in combined organ transplantation literature<sup>3, 4</sup>. The dominant long-term complication has been end-stage renal failure secondary to calcineurin inhibitor (CNI) nephropathy-a well-recognised sequela of long-term CNI exposure<sup>27</sup>-necessitating haemodialysis via arteriovenous fistula. More recently, the patient sustained a low-impact femoral fracture reflecting steroid-associated osteoporosis, with subsequent prolonged hospitalisation, deconditioning, rotator cuff tear, and bilateral upper limb neuromuscular symptoms under active investigation. This case contributes exceptional 35-year outcome data in a field where long-term follow-up beyond ten to fifteen years remains sparse.</p>","PeriodicalId":12669,"journal":{"name":"Global Cardiology Science & Practice","volume":"2026 4","pages":"e202638"},"PeriodicalIF":0.0000,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13613128/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Cardiology Science & Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21542/gcsp.2026.38","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Combined heart-liver transplantation (CHLT) is an exceptionally rare multi-organ procedure undertaken in patients with concurrent end-stage cardiac and hepatic disease, or in those with inherited metabolic disorders-most notably homozygous familial hypercholesterolaemia (HoFH)-in which defective hepatic LDL receptor (LDL-R) function drives progressive and otherwise irreversible cardiovascular injury. We report a 35-year follow-up of a female patient who underwent simultaneous orthotopic cardiac and liver transplantation on 13 September 1990 for HoFH complicated by severe ischaemic cardiomyopathy and aortic valve stenosis. Pre-operative serum low-density lipoprotein cholesterol (LDL-C) was 13 mmol/L, refractory to all pharmacological interventions available at the time. Transplantation produced immediate normalisation of LDL-C to 2.1 mmol/L, reflecting instantaneous restoration of donor hepatic LDL-R function-consistent with the landmark observations reported by Bilheimer, Goldstein, Brown, and Starzl1, 2. This normalisation has been broadly maintained across three and a half decades of follow-up. Lipid-lowering therapy was commenced post-operatively to augment the normalised lipid profile, and dramatic regression of tendon xanthomata was documented within six months of transplantation11. Cardiac graft function has remained preserved, with ejection fraction (EF) of 64-68% on recent echocardiography and no inducible ischaemia on sequential myocardial perfusion scintigraphy (MPS) in May 2025. Progressive cardiac allograft vasculopathy (CAV) has been identified on coronary CT angiography (CTCA) in 2024 but without haemodynamic consequence. Rejection burden across 35 years has been remarkably low-comprising a mild episode at three weeks post-transplant and a single biopsy-confirmed Grade 1R episode in 2013-consistent with the hepatic immunological privilege hypothesis first elaborated by Calne and subsequently substantiated in combined organ transplantation literature3, 4. The dominant long-term complication has been end-stage renal failure secondary to calcineurin inhibitor (CNI) nephropathy-a well-recognised sequela of long-term CNI exposure27-necessitating haemodialysis via arteriovenous fistula. More recently, the patient sustained a low-impact femoral fracture reflecting steroid-associated osteoporosis, with subsequent prolonged hospitalisation, deconditioning, rotator cuff tear, and bilateral upper limb neuromuscular symptoms under active investigation. This case contributes exceptional 35-year outcome data in a field where long-term follow-up beyond ten to fifteen years remains sparse.

心脏和肝脏联合移植治疗纯合子家族性高胆固醇血症:术后35年的结果。
联合心脏-肝移植(CHLT)是一种罕见的多器官移植手术,适用于同时患有终末期心脏和肝脏疾病的患者,或遗传性代谢疾病(最明显的是纯合子家族性高胆固醇血症(HoFH))患者,其中肝脏LDL受体(LDL- r)功能缺陷导致进行性和其他不可逆的心血管损伤。我们报告了一名女性患者的35年随访,该患者于1990年9月13日因HoFH合并严重缺血性心肌病和主动脉瓣狭窄而同时接受了原位心脏和肝脏移植。术前血清低密度脂蛋白胆固醇(LDL-C)为13 mmol/L,对当时可用的所有药物干预均难治。移植使LDL-C立即恢复正常至2.1 mmol/L,反映了供体肝脏LDL-R功能的瞬时恢复,这与Bilheimer、Goldstein、Brown和starz1报道的具有里程碑意义的观察结果一致。在接下来的35年里,这种正常化大体上得到了维持。术后开始降脂治疗以增加正常的血脂水平,移植后6个月内肌腱黄瘤显著消退11。心脏移植功能保持不变,近期超声心动图显示射血分数(EF)为64-68%,2025年5月序贯心肌灌注显像(MPS)显示无诱导性缺血。进行性心脏异体移植血管病变(CAV)在2024年冠状动脉CT血管造影(CTCA)上被发现,但没有血流动力学后果。35年来的排斥负担非常低,包括移植后3周的轻度发作和2013年一次活检证实的1R级发作,这与Calne首先阐述的肝脏免疫特权假说一致,随后在联合器官移植文献中得到证实。主要的长期并发症是钙调磷酸酶抑制剂(CNI)肾病继发的终末期肾衰竭,这是一种公认的长期CNI暴露的后遗症,需要通过动静脉瘘进行血液透析。最近,该患者发生低冲击性股骨骨折,反映了类固醇相关性骨质疏松症,随后长期住院,身体状况恶化,肩袖撕裂,双侧上肢神经肌肉症状正在积极调查中。该病例提供了特殊的35年结果数据,在该领域,超过10至15年的长期随访仍然很少。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Global Cardiology Science & Practice
Global Cardiology Science & Practice Medicine-Cardiology and Cardiovascular Medicine
CiteScore
1.60
自引率
0.00%
发文量
20
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书